Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up pan-tumor study of cancer survivors previously treated in nivolumab trials
jRCT2080225364Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of nivolumab in cancer (2 arms), sponsored by Bristol Myers Squibb. Started Aug 2020; status: recruiting.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2080225364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225364.